Thomas Hwang, M.D.

Thomas Hwang, M.D., is an Assistant Professor of medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine at Brigham and Women’s Hospital. A physician and health policy researcher, his work focuses on the evaluation, approval, and use of new medicines, particularly in cancer care. At Alosa, he focuses on understanding and disseminating the most current unbiased evidence on new prescription drugs.

Dr. Hwang has published over 100 peer-reviewed papers, including in the New England Journal of Medicine, JAMA, Lancet, and Lancet Oncology. He serves as the only US-based member of the European Society for Medical Oncology’s Working Group on the Magnitude of Clinical Benefit Scale, and in 2023 he was named one of STAT’s “Wunderkinds” as one of the nation’s leading experts on pharmaceutical regulation. He has testified before the US House of Representatives, the US Trade Representative, and the Food and Drug Administration. Previously, Dr. Hwang was a Visiting Expert at the European Medicines Agency; he also has worked at the World Health Organization and the White House and in the financial industry. He received his undergraduate and medical degrees from Harvard.